VivoSeq
Neurology

Multiple Sclerosis (MS)

3

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Multiple Sclerosis (MS) is an early-stage landscape with 3 programs across 4 companies. The most active players are Nanjing Legend Biotech Co., Novartis, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nanjing Legend Biotech Co.

1 program

Phase 1Novartis logo

Novartis

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Active, not recruiting1 · 25%
Recruiting1 · 25%
Not yet recruiting1 · 25%
Withdrawn1 · 25%

Clinical Trials

Trial Activity

INFORM - Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-Based Drug Utilisation Study in Finland and Sweden
Active, not recruiting·Bayer logoBayer·N/A·NCT06053749·4 enrolled
A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Recruiting·UUniversity of California, San Francisco·Preclinical·NCT05359653·74 enrolled
An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT07676266·18 enrolled
An Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Withdrawn·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06869278

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)